Estamos realizando la búsqueda. Por favor, espere...
1575
37
170
28821
4394
2595
347
299
Abstract: Aim: To describe patient characteristics, effectiveness and safety in a real-world population treated with niraparib in the Spanish expanded-access programme. Patients and methods: This retrospective observational study included women with platinum-sensitive recurrent high-grade serous ovarian cancer who received maintenance niraparib within the Spanish niraparib expanded-access programme. Eligible patients had received ?2 previous lines of platinum-containing therapy, remained platinum-sensitive after the penultimate line of platinum and had responded to the most recent platinum-containing therapy. Niraparib dosing was at the treating physician's discretion (300 mg/day fixed starting dose or individualised starting dose [ISD] according to baseline body weight and platelet count). Safety, impact of dose adjustments, patient characteristics and effectiveness were analysed using data extracted from medical records. Results: Among 316 eligible patients, 80% had BRCA wild-type tumours and 66% received an ISD. Median niraparib duration was 7.8 months. The most common adverse events typically occurred within 3 months of starting niraparib. Median progression-free survival was 8.6 (95% confidence interval [CI] 7.6-10.0) months. One- and 2-year overall survival rates were 86% (95% CI 81-89%) and 65% (95% CI 59-70%), respectively. Dose interruptions, dose reductions, haematological toxicities and asthenia/fatigue were less common with ISD than fixed starting dose niraparib, but progression-free survival was similar irrespective of dosing strategy. Subsequent therapy included platinum in 71% of patients who received further treatment. Conclusion: Outcomes in this large real-world dataset of niraparib-treated patients are consistent with phase III trials, providing reassuring evidence of the tolerability and activity of niraparib maintenance therapy for platinum-sensitive recurrent ovarian cancer.
Fuente: European Journal of Cancer, 2022, 182, 3-14
Editorial: Elsevier
Año de publicación: 2022
Nº de páginas: 12
Tipo de publicación: Artículo de Revista
DOI: 10.1016/j.ejca.2022.12.023
ISSN: 0959-8049
Url de la publicación: https://doi.org/10.1016/j.ejca.2022.12.023
Leer publicación
CUEVA, JUAN F
PALACIO, ISABEL
CHURRUCA, CRISTINA
HERRERO, ANA
PARDO, BEATRIZ
CONSTENLA, MANUEL
SANTABALLA, ANA
MANSO, LUIS
ESTÉVEZ, PURIFICACIÓN
MAXIMIANO, CONSTANZA
LEGERÉN, MARTA
MARQUINA, GLORIA
ANA DE JUAN FERRE
QUINDÓS, MARÍA
SÁNCHEZ, LUISA
BARQUIN, ARANTZAZU
FERNÁNDEZ, ISAURA
MARTÍN, CRISTINA
JUÁREZ, ASUNCIÓN
MARTÍN, TERESA
Volver